NCT03292133 - A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

December 31, 2021

Study Completion Date

March 4, 2025

Conditions

Lung Cancer

Interventions

DRUG

EGF816

EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

DRUG

Gefitinib

Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying

Trial Locations (1)

Massachusetts General Hospital, Boston